Mitochondrially-Derived Peptide · Protocol Guide
MOTS-c: The Mitochondrial Peptide Guide
MOTS-c is the most-studied mitochondrially-derived peptide. The mechanism is sound. The mouse data is strong. The human RCT data is thin. WADA prohibited as of January 1, 2025. This guide separates the three.
- FDA Status
- Off-Label, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: MOTS-c has compelling rodent data and almost no human RCT data. Marketing language calling it an exercise mimetic is overstating the human evidence. We are direct about that.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.On this page
Section 01
What MOTS-c Actually Is
MOTS-c is a 16-amino-acid mitochondrially-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. The discovery (Lee et al., 2015) that mtDNA encodes functional peptides which act as retrograde signaling molecules opened a new biological category. MOTS-c is the most-studied member of that category.
Functionally, MOTS-c is an AMPK activator. Under metabolic stress (exercise, caloric restriction, fasting), endogenous MOTS-c is upregulated and translocates to the nucleus where it regulates gene expression. Exogenous MOTS-c is being studied as a metabolic intervention for insulin resistance, age-related decline, and mitochondrial dysfunction.
16
Amino acids in the MOTS-c peptide chain
~12x
Endogenous MOTS-c upregulation in skeletal muscle during exercise
2025
WADA added MOTS-c to the Prohibited List, January 1
Section 02
Who It Is Actually For
| Profile | Fit | Rationale |
|---|---|---|
| 35 to 55, metabolic dysfunction (elevated fasting glucose, HOMA-IR, prediabetes) | Best Fit | Circulating MOTS-c is measurably lower in insulin-resistant individuals. The AMPK mechanism directly addresses glucose metabolism. |
| 45 to 70, longevity-focused, exercise-limited | Best Fit | Mouse data shows late-life intervention improves physical capacity. Most-compelling preclinical signal is in this profile. |
| Scientifically literate biohacker | Good Fit | The absence of human RCT data is a known limitation this profile accepts. Will measure metabolic markers and treat as n=1 experiment. |
| Women with metabolic syndrome, PCOS, perimenopausal insulin resistance | Uncertain | Research is heavily male-skewed. Sex-specific dosing and effects have not been studied. Physician-supervised monitoring especially important. |
| Competitive athletes in WADA-regulated sports | Poor Fit | MOTS-c added to WADA Prohibited List January 1, 2025 (S4.4.1 AMPK activators). Sanctions apply. |
| Persons seeking an exercise substitute | Poor Fit | No human evidence MOTS-c produces exercise-like benefits in the absence of exercise. Exercise itself raises endogenous MOTS-c ~12-fold. |
Profile
Fit
Rationale
Profile
Fit
Rationale
Profile
Fit
Rationale
Profile
Fit
Rationale
Profile
Fit
Rationale
Profile
Fit
Rationale
Section 03
How It Works
MOTS-c is translated from an open reading frame within the 12S rRNA gene of the mitochondrial genome, a location previously considered non-coding. It is produced in virtually every tissue that contains mitochondria and circulates as a hormone in blood plasma.
Under metabolic stress (exercise, fasting, caloric restriction), MOTS-c is upregulated and translocates to the nucleus. Once there, it directly regulates nuclear gene expression, acting as a retrograde signal that communicates mitochondrial status to the cell's transcriptional machinery. The primary metabolic pathway is the folate-AICAR-AMPK axis: MOTS-c disrupts one-carbon metabolism, leading to intracellular accumulation of AICAR, which activates AMP-activated protein kinase (AMPK).
AMPK activation drives downstream effects relevant to metabolic health: increased GLUT4 translocation (more glucose uptake in skeletal muscle without requiring insulin), upregulation of fatty acid oxidation, suppression of hepatic glucose production, and stimulation of mitochondrial biogenesis. These effects explain the metabolic benefits seen in rodent models.
Section 04
Realistic Expectations
MOTS-c operates at the level of cellular metabolism and gene expression. Changes in body composition, insulin sensitivity, and functional capacity develop over weeks to months. Any protocol promising dramatic early results is describing placebo or confounding lifestyle factors.
Biochemical Activity, No Perceptible Change
Cellular AMPK signaling and GLUT4 mobilization at the biochemical level. Nothing subjective is likely. MOTS-c is not a stimulant and not a next-morning peptide.
Possible Early Metabolic Shifts
Some users report improved exercise tolerance and modest energy improvements. Fasting glucose may begin to trend lower in metabolically-dysregulated patients.
Measurable Metabolic Markers
Fasting glucose, HOMA-IR, and hsCRP improvements accumulate. Body composition shifts in patients combining MOTS-c with training begin to appear.
Full Protocol Evaluation
The earliest meaningful window to assess body composition and functional capacity changes. Patients who consistently train alongside the protocol see the strongest signal.
Section 05
Dosing Protocol
No FDA-approved dose exists. The community standard evolved from extrapolation of rodent dosing. RxPepsDirect prescribes based on the protocols that have accumulated the most clinical experience.
| Context | Dose | Frequency | Evidence Basis |
|---|---|---|---|
| RxPepsDirect Standard Protocol | 0.4 mg (20 units) | 3 times per week, subcutaneous | Clinical Practice |
| Higher-Dose Community Protocol | 0.5 to 1 mg | 3 times per week | Community Anecdote |
| Daily Microdose Protocol | 0.1 to 0.2 mg | Daily | Mechanistic Rationale |
| Exercise-Coupled Protocol | 0.4 mg (20 units) | Training days, 30 to 60 min pre-workout | Mechanistic Rationale |
Context
Dose
Frequency
Evidence Basis
Context
Dose
Frequency
Evidence Basis
Context
Dose
Frequency
Evidence Basis
Context
Dose
Frequency
Evidence Basis
Subcutaneous injection into abdominal fat. Standard insulin syringe (28 to 31 gauge, 6 to 8 mm needle). For the standard and higher-dose protocols, most patients inject in the morning for consistency. Patients running the exercise-coupled protocol inject 30 to 60 minutes before training so exogenous MOTS-c reaches systemic circulation as endogenous MOTS-c begins its exercise-induced rise. The mechanistic rationale is that AMPK and GLUT4 priming compounds with the same pathways exercise activates. On rest days, the exercise-coupled protocol skips the dose; the standard and microdose protocols continue as scheduled. None of these timing windows have been compared head-to-head in human trials; your prescribing physician will recommend the schedule that best fits your training pattern and goals.
Side Effects and How to Manage Them
MOTS-c has a limited human safety dataset — all available evidence is from preclinical studies and a small number of human participants. The side effects reported are generally mild and injection-related. Exercise caution, monitor closely, and report any unexpected effects to your provider.
| Side Effect | Frequency | When | Mitigation |
|---|---|---|---|
| Injection site redness or mild pain | Common (10–20%) | Weeks 1–3 | Rotate injection sites. Allow vial to warm to room temperature before injecting |
| Initial fatigue (days 1–3) | Uncommon (5–10%) | First 3 days | Brief adaptation to AMPK pathway activation. Resolves without intervention |
| Unknown long-term effects | Human data insufficient to characterize | Unknown | Report any new or unexpected symptoms to your provider — this compound lacks the human trial data to fully characterize the safety profile |
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Weekly Self-Monitoring Protocol
MOTS-c monitoring focuses on the metabolic and exercise-response signals it is hypothesized to affect.
| Metric | Frequency | Tool | Signal to Report |
|---|---|---|---|
| Fasting glucose (if available) | Weekly | Home glucometer | Unexpected downward trend below 65 mg/dL — contact provider |
| Exercise tolerance / recovery (subjective 0–10) | Weekly after each training session | Training log or phone note | No improvement after 4 weeks — discuss protocol |
| Energy level (0–10) | Daily | Phone note | No improvement by week 3 |
| Injection site appearance | Each injection | Visual inspection | Redness or swelling lasting more than 48 hours |
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Section 06
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 07
Stacking
Pairs Well With
Tesamorelin / GH secretagogues
Visceral fat reduction plus metabolic improvement. Different pathways, complementary.
BPC-157
Tissue repair via different pathway. No mechanistic overlap.
NAD+ therapy
Cellular energy via NAD+/NADH redox. Complementary to AMPK activation.
Consistent training
Exercise raises endogenous MOTS-c ~12-fold. Combining exogenous MOTS-c with training compounds the effect.
Approach With Caution
Metformin (clinical use)
Both activate AMPK. Patients on metformin should discuss with their PCP before starting MOTS-c.
Insulin or sulfonylureas
Risk of additive glucose-lowering. Monitor for hypoglycemia. Physician supervision required.
Active pregnancy
No safety data. Avoid.
Competitive sport under WADA
Banned January 1, 2025. Sanctions apply regardless of prescription status.
Section 08
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Other Online Clinics | $200 to $400 per month | Visit fees often bundled | Per-cycle pricing varies. Verify before committing. |
| Optimal Balance Pharmacy + RxPepsDirect | $80 per 10 mg vial, paid to pharmacy | $39 visit fee, paid to RxPepsDirect | Pre-reconstituted, FedEx overnight, labeled to you. |
| Gray Market (Research Vendor) | $30 to $80 per vial | None (no prescription) | Research-grade. No physician, no quality verification. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$80 per 10 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including metabolic baseline review, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect.
Section 09
Legal Access (Including WADA)
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Off-Label, Legal Practice
Standard and legal in U.S. medicine
WADA Prohibited 1/1/2025
S4.4.1 AMPK activators category
Section 10
Community Q&A
Is MOTS-c really an exercise mimetic?
The mechanism overlaps meaningfully with exercise. The effect in the absence of exercise has not been demonstrated in humans. Exercise raises endogenous MOTS-c ~12-fold. Treat MOTS-c as an adjunct to training, not a substitute for it.
Will it lower my blood sugar?
Mechanistically, yes. Mouse data and human metabolic pathway analysis both support glucose lowering through GLUT4 mobilization. If you are on insulin or sulfonylureas, monitor for hypoglycemia. Discuss with your prescribing physician.
Should I worry about WADA if I'm not a pro athlete?
The WADA Prohibited List applies to WADA-affiliated competitive testing (Olympic, NCAA, professional sports). It is not U.S. drug law. Most patients are not subject to WADA testing. If you compete at any level under a WADA-affiliated body, the ban applies.
What is the K14Q variant?
A loss-of-function MOTS-c polymorphism (m.1382A>C) that produces a non-functional MOTS-c protein. Carriers have elevated type 2 diabetes risk in sedentary populations and may be among the strongest responders to exogenous MOTS-c supplementation. Not yet standard to screen for.
What happens if Optimal Balance is out of stock?
Your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 11
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your MOTS-c under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your metabolic baseline, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
The guide flags the human evidence gap, the exercise-mimetic overstatement, the WADA prohibition, and the metformin / hypoglycemia caution. We do not hide limitations.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription. Not subject to U.S. controlled-substance scheduling.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID: 25738459
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID: 33473109
- Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021. PMID: 33495401
- Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents. Pediatr Diabetes. 2018. PMID: 30022589
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Longevity coenzyme
NAD+ protocol guide: sirtuin activation, the bioavailability problem, and IV vs subcutaneous
Oral supplements have a bioavailability problem the marketing rarely admits. IV produces the flush. Subcutaneous is the at-home middle ground. Not proven to extend lifespan.
Mitochondria-targeted tetrapeptide
Elamipretide (SS-31) guide: cardiolipin-stabilizing mitochondria-targeted peptide
Cleanest mechanism in the mitochondrial-support category. Late-stage FDA program (Barth syndrome). Phase III ReCLAIM-2 missed primary endpoint. Available through 503A compounding.
Mitochondrial cognitive capsule (MB-5 to MB-25)
Methylene Blue guide: mitochondrial electron carrier, MAO-A inhibitor, the SSRI contraindication
Mitochondrial electron carrier at low dose, MAO-A inhibitor at any dose. SSRIs, SNRIs, MAOIs, TCAs are hard contraindications. Hormetic dose curve. Medication screening is mandatory.
ERR agonist exercise mimetic protocol
SLU-PP-332 protocol guide: the ERR agonist exercise mimetic, the mouse data, and the total absence of human evidence
An oral small molecule that switches on the ERR exercise gene program. Every result so far is from mice and cells, with zero human data. Honest about the gap and the anti-doping attention.
Longevity peptide protocol
Epithalon (Epitalon) protocol guide: the telomere peptide, the Khavinson studies, and the limits of the evidence
Pineal tetrapeptide, telomerase reactivation, the in vitro telomere result, the 266-patient extract trial, fly and mouse lifespan data, WADA S0 status, and the 503A pathway. Honest about how thin and unreplicated the human proof is.
Continue reading